Evidence map›Paper›PMID 37762274›Full record

ArticleInternational journal of molecular sciences2023

Recovering What Matters: High Protein Recovery after Endotoxin Removal from LPS-Contaminated Formulations Using Novel Anti-Lipid A Antibody Microparticle Conjugates.

Cristiane Casonato Melo, Alexandra C Fux, Martin Himly, Neus G Bastús, Laura Schlahsa, Christiane Siewert, Victor Puntes, Albert Duschl, Isabel Gessner, Jonathan A Fauerbach

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Aptamer-functionalized aggregation-induced emission micelles for integrated detection and photodegradation of lipopolysaccharides.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  3. Article
  4. Article
  5. Editorial of Special Issue "Current Trends in Chemistry Towards Biology".International journal of molecular sciences · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Cristiane Casonato MeloChemical Biology Department, R&D Reagents, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0000-0003-1013-585X
Alexandra C FuxChemical Biology Department, R&D Reagents, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0000-0001-8745-829X
Martin HimlyDivision of Allergy & Immunology, Department of Biosciences & Medical Biology, Paris Lodron University of Salzburg, 5020 Salzburg, Austria.ORCID 0000-0001-5416-085X
Neus G BastúsInstitut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08036 Barcelona, Spain.ORCID 0000-0002-3144-7986
Laura SchlahsaChemical Biology Department, R&D Reagents, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Christiane SiewertChemical Biology Department, R&D Reagents, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Victor PuntesInstitut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08036 Barcelona, Spain.
Albert DuschlDivision of Allergy & Immunology, Department of Biosciences & Medical Biology, Paris Lodron University of Salzburg, 5020 Salzburg, Austria.ORCID 0000-0002-7034-9860
Isabel GessnerChemical Biology Department, R&D Reagents, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0000-0001-9674-161X
Jonathan A FauerbachChemical Biology Department, R&D Reagents, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0000-0002-1540-0352
Miltenyi Biotec (Germany) · DEUniversity of Salzburg · ATConsejo Superior de Investigaciones Científicas · ESInstitució Catalana de Recerca i Estudis Avançats · ES

Funding

European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant No 812661, H2020-MSCA-ITN-2018-812661 (ENDONANO)
6 · The paper itself

Abstract

Endotoxins or lipopolysaccharides (LPS), found in the outer membrane of Gram-negative bacterial cell walls, can stimulate the human innate immune system, leading to life-threatening symptoms. Therefore, regulatory limits for endotoxin content apply to injectable pharmaceuticals, and excess LPS must be removed before commercialization. The majority of available endotoxin removal systems are based on the non-specific adsorption of LPS to charged and/or hydrophobic surfaces. Albeit effective to remove endotoxins, the lack of specificity can result in the unwanted loss of essential proteins from the pharmaceutical formulation. In this work, we developed microparticles conjugated to anti-Lipid A antibodies for selective endotoxin removal. Anti-Lipid A particles were characterized using flow cytometry and microscopy techniques. These particles exhibited a depletion capacity > 6 ×10

Indexed as

EndotoxinsLipopolysaccharidesDrug CompoundingHumansLimulus TestMembrane ProteinsEndotoxinsLipopolysaccharidesMembrane ProteinsbioconjugationLALLPS contaminationNTApolystyrene particlessupramolecular structures

Identifiers

PMID37762274
PMCPMC10531372
OpenAlexW4386686781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.